Sarcoidosis
An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.
Subtype terms (2)
More specific conditions that are subtypes of Sarcoidosis in the MeSH hierarchy.
- Sarcoidosis, Pulmonary
35 drugs (25 approved, 10 experimental)
- Uveoparotid Fever
Drugs by status
Approved for this indication (3)
Phase 4 trials (9)
Phase 3 trials (9)
Phase 2 trials (26)
- levofloxacin
- ara 290
- Iberdomide
- bardoxolone
- golimumab
- ethambutol
- rifampin
- allogeneic stem cells
- Brepocitinib
- adalimumab
- nicotine
- sarilumab
- sirolimus
- cyclophosphamide
- abatacept
- dapsone
- treprostinil
- ustekinumab
- azithromycin
- rituximab
- fludeoxyglucose f-18
- rubidium chloride rb-82
- abrocitinib
- autologous hematopoietic stem cells
- 68ganota-anti-mmr-vhh2
- deucravacitinib
Phase 1 trials (3)
Organizations
Organization Involved with Phase 4 Indications (20)
- Mallinckrodt
- University of Pittsburgh
- Albany Medical College
- Henry Ford Health System
- Ohio State University
- Postgraduate Institute of Medical Education and Research
- University of Maryland
- University of Ottawa
- University of Rochester
- Mayo Clinic
- University of California, San Francisco
- University of Cincinnati
- St. Antonius Hospital, Nieuwegein
- University of Paris
- Erasmus University Rotterdam
- University of Illinois at Chicago
- Inova Health System
- American Thoracic Society
- Imperial College London
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (16)
- Actelion
- Celgene
- Cephalon
- United Therapeutics
- Roche
- Gilead Sciences
- Centocor
- Eli Lilly
- University of Milan
- University of South Carolina
- University of Turku
- Medical University of South Carolina
- University of North Carolina at Chapel Hill
- Agenzia Italiana del Farmaco
- Canadian Institutes of Health Research (CIHR)
- Assistance Publique - Hôpitaux de Paris
Organization Involved with Phase 2 Indications (28)
- Abbott
- Bristol-Myers Squibb
- Pfizer
- Novartis
- Araim Pharmaceuticals, Inc.
- Exalenz Bioscience LTD.
- Reata Pharmaceuticals, Inc.
- Virginia Clinical Research, Inc.
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pennsylvania
- American Heart Association
- Eastern Virginia Medical School
- Northwestern University
- Stanford University
- University of Florida
- University of Hull
- Virginia Commonwealth University
- Wake Forest University
- Yale University
- University of Chicago
- Vanderbilt University
- Wright State University
- University of Vienna
- aTyr Pharma
- Medical University of Vienna
- Bellerophon Therapeutics
- American Association for the Study of Liver Diseases
- Foundation for Sarcoidosis Research
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (7)